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Transforming the cell surface through proteolysis 
Laura L Kiessling and Eva J Gordon 
Protein shedding, or the proteolytic cleavage of a protein from 
the surface of a cell, is emerging as an important mechanism in 
the regulation of cellular activity but it is poorly understood. 
Growing evidence suggesting that protein shedding and 
protein function are closely linked may lead to new strategies 
for the treatment of a wide range of diseases. 
Address: Departments of Chemistry and Biochemistry, University of 
Wisconsin-Madison, Madison, WI 53706, USA. 
Correspondence: Laura L Kiessling 
E-mail: kiessling@chem.wisc.edu 
Chemistry 81 Biology March 1998,5:R49-R62 
http://biomednet.com/elecref/10745521005R0049 
0 Current BioioQy Ltd ISSN 1074-5521 
Introduction 
Cells have the remarkable ability to direct the functions 
and activities of their thousands of proteins through 
several mechanisms. One of these is phosphorylation - a 
reversible modification that affects function by changing 
protein-protein interaction propensities. An alternative 
and more permanent way to direct cellular processes is by 
proteolysis. Intracellularly, proteolysis can regulate the 
presence of specific proteins, influencing fundamental 
processes such as the cell cycle or apoptosis, and proteoly- 
sis regulates important processes outside the cell, such as 
cell migration and wound repair. Proteolysis can also func- 
tion as a control mechanism on the cell surface. For 
example, the G-protein-coupled thrombin receptor can be 
activated by limited proteolysis [l]: thrombin cuts the 
amino terminus of its receptor, causing a conformational 
change that activates the receptor. Thus, regulated prote- 
olysis has an important role on the cell surface. 
This review focuses on the importance of proteolysis in the 
release of the extracellular portion of a protein by cleavage 
at the cell surface, referred to here as protein shedding. 
The term protein shedding has been used to describe the 
loss of molecules from the cell surface either through enzy- 
matic cleavage by proteases or lipases, or by exocytosis in 
membrane-derived vesicles. Here, however, protein shed- 
ding will be used exclusively to describe the proteolytic 
cleavage of proteins from the surface of the cell. 
A number of different cell types shed proteins from their 
cell surface and the proteins released are also diverse, 
including cytokines and cytokine receptors, growth factors 
and growth factor receptors, cell-adhesion molecules, Fc 
receptors, and G-protein-coupled receptors (Table 1). 
These proteins have a wide range of functions, and there 
is a growing interest in exploring the relationship between 
protein shedding and protein function. 
Recent reviews have provided excellent discussions about 
the characteristics of the enzymes involved in proteolytic 
release, the cleavage of leukocyte membrane molecules, 
and the generation and function of soluble cytokine recep- 
tors and growth factors [Z-6]. Here, we focus on the events 
that liberate the ectodomain of a transmembrane protein 
(Figure 1 and Table l), which we have classified into four 
main categories. The first group is comprised of the shed- 
ding processes induced by cellular activators, the second 
group consists of shedding processes that appear to be con- 
stitutive, the third comprises proteolytic cleavage events 
mediated by antibodies, and we also discuss emerging evi- 
dence suggesting that some receptors are proteolyticahy 
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Shedding method 
Activation 
Antibody1 .CD43 (antiCD43), 
CD44 (antXD44, anti-CDSS), 
CD62L (anti-CDBPL, 
anti-Leu-13, anti CD45, 
anti-CD1 6, anti-CD95), 
CD23 (antiCD20) 
LigandY 
Table 1 
Proteins that are shed from the cell surface. 
Cell adhesion 
molecules 
CD43*+, CD44*5, 
CD62L*+, CD23* 
Proteins released 
Cytokines/ Growth factors/ G-protein coupled 
cytokine receptors growth factor receptors receptors Miscellaneous 
TNFa*, TNFR-l*H$ proTGFcc*S, CSF-1 R*, TSHR CD1 4*#, CD1 6-l* 
TNFR-II**,IL-1 RII*, HGFR*, c-kit receptor*§, CD1 6-ll*,CD30*, 
IL-4R*, IL-6R*# TrkA neurotrophin receptor* Fas’, LAR*, ACE*, 
pAPP*, class I MHC’, 
syndecan* 
CD1 4 (anti-CD1 4) 
CD62L (neoglycopolymer), IL-3R (IL-3), 
CD44? (hyaluronate), TNFR-I (TNFa), 
CD43? TNFR-II (TNFa) 
TrkA neurotrophin TSHR (TSH), CD1 4? (LPS) 
receptor (NGF) V2 vasopressin receptor 
(photoreactive 
vasopressin agonist) 
The symbols designate those cell-surface molecules that are shed in 
response to the corresponding activator. This list is not all inclusive; 
each molecule has not necessarily been tested with every activating 
agent: *PMA, +fMLP, *LPS, %a !z+ ionophores, #toxins. IShed molecule 
(antibody or antibodies that induce the shedding). %hed molecule 
(ligand that induces its shedding). ACE, angiotensin converting 
cleaved in response to ligand binding. Ligand-induced pro- 
teolysis is a potential mechanism for regulating receptor- 
ligand interactions, and extends a relationship between the 
function and regulation of receptors. 
Activation-induced shedding 
Cellular stimulants can induce the shedding of many pro- 
teins and also cause cellular activation and concomitant 
changes in cell behavior. The release of protein ecto- 
domains appears to be one way for the cell to change the 
characteristics of its surface, eliminating activities that are 
no longer necessary or are counterproductive. Although 
the precise relationship between the new behaviour 
adopted by the cell and the effects of protein shedding 
remains to be determined, there is circumstantial evidence 
suggesting that they are functionally linked. For example, 
when leukocytes become activated they shed the leuco- 
cyte antigen CD43 from their surface, and also become 
more able to adhere to target cells. CD43 is a highly 
anionic sialomucin, proposed to function as an ‘anti-adhe- 
sive’ molecule. It is found in high concentrations on circu- 
lating white blood cells, and towers over the cell surface, 
extending -45 nm beyond the membrane [7]. The nega- 
tive charges on CD43 are believed to prevent leukocyte 
aggregation and undesired adhesion events by both elec- 
trostatic and sterid repulsion. When leukocytes become 
activated, they shed CD43 from the surface, rendering the 
enzyme; PAPP, P-amyloid precursor protein; TNF, tumor necrosis 
factor; TSH, thyrotropin; IL, interleukin; TGF, transforming growth 
factor; MHC, major histocompatibility complex; CSF, colony 
stimulating factor; HGF, hepatocyte growth factor; NGF, nerve growth 
factor; PMA, phorbol 1 P-myristate 13-acetate; fMLP, 
formylmethionylleucyIphenylalanine: LPS, lipopolysaccharide. 
cell surface conducive to adhesive interactions suggesting 
that CD43 shedding is an important part of the activation 
process [8]. Similar persuasive explanations for the func- 
tional roles of other shedding events have been suggested, 
but, as it is currently difficult to separate individual shed- 
ding events and thus study the functional effect of shed- 
ding one protein at a time, it has been hard to provide 
rigorous tests of these explanations. 
Little is known about the pathways by which cellular 
stimulants induce the release of extracellular proteins. 
Many different agents have this capacity, including 
phorbol esters, chemotactic peptides, calcium ionophorcs, 
cytokines and growth factors (Figure Za). These agents all 
initiate signal transduction, but use a variety of different 
pathways, making it difficult to identify the branch of the 
pathway that triggers protein release. Most studies of acti- 
vation-promoted protein shedding have used phorbol 
esters (such as phorbol myristate acetate [PMA]) to stimu- 
late protein kinase C (PKC) activity and some information 
about how cell srimulation leads to shedding has emerged 
from these investigations. 
Phorbol esters induce collective shedding of a wide 
variety of cell-surface molecules, resulting in the release of 
cytokines (e.g., TNF-a), growth factors (e.g., proTGF-a), 
receptors (e.g., TNF receptor, IL-ZR), cell-adhesion 
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Figure 1 
The liberation of the ectodomain of 
transmembrane proteins (protein shedding). 
(a) Activation-induced shedding. 
(b) Constitutive shedding. (c) Antibody- 
induced shedding. (d) Ligandinduced 
shedding. 
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molecules (e.g., L-selectin), enzymes (e.g., angiotensin 
converting enzyme) and proteins of unknown function 
(e.g., the amyloid precursor protein) [4,9,10]. The induc- 
tion of shedding by phorbol esters suggests that PKC may 
act directly to cause protein shedding. Activated PKC 
phosphorylates serine and threonine residues in the cyto- 
plasmic domains of selected proteins, but for many of the 
shed proteins the presence of a cytoplasmic domain, and 
therefore a potential intracellular signaling or recognition 
sequence, is not required for cleavage [ll,lZ]. Addition- 
ally, many of the proteins released from the cell surface 
using phorbol esters are not phosphorylation substrates for 
PKC. Collectively, these results suggest that PKC does 
not directly promote protein shedding but is perhaps an 
upstream modulator of these proteolytic events. 
The sequences of protease cleavage sites for several shed 
proteins have been determined and they have no obvious 
similarities. When the extracellular sequences of shed 
proteins are appended to proteins that are resistant to 
shedding, hovvever, the resulting chimeric proteins are sus- 
ceptible to proteolytic release [11,13], suggesting that pro- 
teins are released from the cell surface when they have 
either a sequence that adopts a specific conformation or 
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(a) 
Figure 2 
Chemical structures of molecules that 
promote or inhibit the shedding of cell-surface 
proteins. (a) The phorbol ester PMA, the 
fMLP &H, 
chemotactic peptide fMLP and the calcium 
ionophore ionomycin are cellular activators 
that can promote the cleavage of a variety of 
cell-surface molecules. (b) Hydroxamic-acid- 
based peptide-like molecules, such as TAP1 
and BB2116, inhibit the cell-surface 
proteolysis of many proteins. 
(b) 
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one that is conformationally flexible. The apparent lack of 
selectivity has complicated the identification of protease 
responsible for activation-induced shedding [9,10]. 
Most activation-induced shedding processes can be inhib- 
ited by metalloproteinase inhibitors, especially hydroxamic 
acid derivatives (Figure Zb). For example, these agents 
prevent the activation-induced shedding of several pro- 
teins, including TNF-a, p60 and ~80 TNF-receptors, 
L-selectin, TGF-CX, FasL, thyrotropin receptor, and 
angiotensin-converting enzyme [4]. The results suggest 
that at least one essential enzyme in the pathway is a Zn2+- 
dependent metalloproteinase, or perhaps that the mem- 
brane-protein-solubilizing enzyme or enzymes themselves 
are metalloproteinases. Metalloproteinases that are known 
to act extracellularly include matrix metalloproteinases 
(MMPs), the astacin-related bone morphogenetic protein 1 
(BMP-l)/tolloid family of metalloproteinases, and the 
adamalysin-related class of metalloprotease disintegrins, 
which are referred to as ADAMS (a disintegrin and metallo- 
protease domain) or MDCs (metalloprotease/disintegrin/ 
cysteine-rich protein) [14-201. These enzymes probably 
share structural features such as similar zinc-binding sites, 
and they have been classified into a superfamily termed 
‘metzincins’ [Zl]. Given the structural similarities, it 
would be expected that a hydroxamic acid derivative 
could inhibit multiple zinc proteinases. 
Although hydroxamic acids block activation-induced shed- 
ding, metalloproteinases are not necessarily the only pro- 
teases involved in the process. For example, many of the 
metalloproteinases are produced in pro-form, a state in 
which the active-site zinc ion is trapped by cysteine coor- 
dination in a catalytically inactive coordination state. Pro- 
teolysis of the pro-metalloenzymes results in the loss of 
the cysteine ligand (cysteine switch), making the zinc 
center catalytically active. Thus, these enzymes can be 
activated in a proteolytic cascade that could involve extra- 
cellular metallo-proteinases or serine proteases. Inhibition 
data, however, suggest that most PMA-promoted shedding 
events are not blocked by serine protease inhibitors, 
although a highly active protease at the cell surface could 
be inaccessible to the inhibitors [ZZ]. Additionally, natu- 
rally occurring inhibitors of the MMPs (tissue inhibitors of 
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Figure 3 
(a) Activation of one metalloprotease 
with broad substrate specificity 
Activation of a regulatory factor 
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Cellular activation leads to the shedding of many cell-surface proteins. 
(a) Two models for the mechanism of PMA-promoted shedding. 
(b) Domain organization of two distinct metalloprotease/disintegrins 
that cleave pro-TNFa, HuADlO (left) and TACE (right). HuADlO and 
TACE have 49.8% overall similarity. 
metalloproteinase, including TIMP-1, TIMP-2) do not 
diminish protein shedding so, although protease accessibil- 
ity may also be a factor in these studies, the results do 
suggest that R/IMPS may not be the predominant agents 
causing activation-induced protein release. 
Significant research efforts have focused on identifying the 
membrane-associated protease that mediates the prote- 
olytic release of tumor necrosis factor-a (TNF-CX), a 
cytokine involved in inflammation. This search has re- 
sulted in the identification of at least two distinct enzymes 
(Figure 3b), and the genes encoding them have been 
cloned. Two groups identified the same protease, termed 
TNF-a converting enzyme (TACE), which is a member 
of the ADAMS family of disintegrin metalloproteinases 
[23,2-l]. Disruption of the gene encoding TACE in mice 
resulted in lower levels of TNF-a, supporting the idea 
that the TACE enzyme is responsible for endogenous 
TKF-cx processing [23]. The second protein that has been 
identified, HuADlO, can cleave TNF-a, but not other 
proteins that are shed, suggesting it acts specifically [ZS]. 
HuADlO is also a member of the ADAhIs family, which is 
intriguing because ADAhls family proteases have been 
implicated in important processes, including fertilization, 
muscle fusion and development [26,27]. Both TNF-a 
processing enzymes have a zinc metalloproteinase domain 
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and pro-domain, probably a cysteine switch, in addition to 
a disintegrin domain and a cysteine-rich domain in the 
extracellular region (Figure 3b). The functions of these 
regions are not clear, but the disintegrin domain probably 
serves as a site for recognition of either the substrate 
TNF-cx or as a link to the integrins. Because integrins are 
cell-adhesion and signaling molecules involved in cell~ell 
and cell-matrix interactions, the adhesion domain could 
couple integrin function to receptor shedding. In addition, 
the cytoplasmic domains of TACE and HuADlO contain 
proline-rich sequences that could bind to SH3-containing 
proteins. SH3-containing proteins are involved in cell sig- 
naling, suggesting that there may be a connection between 
signal transduction and shedding [28]. Both TACE and 
HuADlO were identified from the same cell line (THP-1). 
so different ADAhI metalloproteinases in the same cell can 
process a single substrate. This provides further impetus 
for elucidating the factors controlling protease activity. 
There are some common features in the activation-induced 
release of proteins. Arribas et a/. [9] obtained genetic evi- 
dence to suggest a common pathway for PhiA-induced 
shedding of protein ectodomains. They identified mutant 
Chinese hamster ovary (CHO) cell lines that did not release 
membrane-anchored transforming growth factor a (TGF-a) 
upon treatment with phorbol ester, and found that these 
mutant cell lines were unable to release the unrelated 
protein ectodomains from L-selectin. the P-amyloid precur- 
sor protein and the interleukin-6 receptor. Two different 
possibilities could account for these results. First, one pro- 
tease of broad specificity can cleave a wide range of cell- 
surface proteins: second, several members of a family of 
related proteases, which cleave several substrates, are acti- 
vated by a specific signaling e\‘ent (Figure 3a). If one pro- 
tease could cleave many cell-surface proteins, disruption of 
a gene encoding a protease that has an unusually broad sub- 
strate specificity could account for the lack of activity. 
Although this is possible. the metalloproteinases, which act 
extracellularly, have been shown to be selective for particu- 
lar protein substrates in e&. If many proteases were acti- 
vated by a specific signalling event (the second possibility) 
mutations in a gene that encodes a single regulatory factor 
would prevent the regulatory factor from activating a variety 
of proteases. The factor could be a protease itself, as many 
proteases are activated by proteolytic cleavage. 
hlost investigations into protein shedding have involved 
cellular activation using phorbol esters, but there is some 
indication that the activation-induced shedding of certain 
receptors may occur by more than one mechanism, which 
is not surprising as different stimulants can trigger distinct 
activation events. For example, the cleavage of the recep- 
tors for intcrleukin-6 and lipopolysaccharide (CD14) is 
induced by Phlh or pore-forming toxins [29]. Although 
both processes are prevented by metalloproteinase 
inhibitors, the toxin-dependent cleavage site was mapped 
to a different position than the site of cleavage induced b) 
phorbol ester, suggesting either the involvement of differ- 
ent proteases in the cleavage or that alterations of the cell 
membrane can cause changes in the cleavage site. ‘I’hus, 
studies of protein shedding that involve different activa- 
tion methods will illuminate the mechanistic pathways 
available for regulating the display of cell-surface proteins. 
Constitutive proteolytic release 
Several proteins, including the TNF receptors, the 
P-amyloid precursor protein, syndecan, L-selectin and the 
thyrotropin receptor, appear to be shed constitutively from 
the surface of cells without cellular stimulation by outside 
agents [4] (Table 1). The mechanism(s) of continuous or 
spontaneous shedding is not known, although, in several 
instances, the process can be inhibited by serine and/or 
metalloproteinase inhibitors, characteristics suggesting that 
constitutive shedding ma): occur by the same, or related, 
proteases used in activation-induced shedding. Sponta- 
neous shedding of receptors may result from the action of 
constitutively active proteases and may be a necessary part 
of the cellular turnover process for cell-surFace molecules. 
In the normal cellular aging process. some loss of cell- 
surface proteins could occur, and this change in protein 
display could arise, in part, from constitutive shedding [30]. 
Investigations of the extracellular proteolysis of ErbB-4, a 
growth factor receptor tyrosine kinase that undergoes con- 
stitutive shedding, reveal an interesting connection be- 
tween extracellular and intracellular proteolysis [31.35]. A 
soluble fragment of ErbB-4 is generated by spontaneous 
shedding or by phorbol-ester-induced proteolys’is and the 
resulting membrane-anchored kinase domain can no 
longer respond to its ligand, but it remains catalytically 
active. Under these circumstances, however, the growth 
factor fragment is ubiquitinated and targeted to the pro- 
teasome for degradation. The intact ErbB-4 receptor is not 
subject to ubiquitination, but extracellular proteolysis 
generates a substrate for polyubiquitination and subsc- 
quent intracellular proteolysis. Unregulated kinase 
domains could function as renegade signaling molecules, 
but this series of proteolytic events eliminates such sub- 
strates. The Met tyrosine kinase appears to use a similar 
pathway, suggesting that this may be a general mechanism 
for eliminating unresponsive signaling molecules [33]. As 
with activation-dependent protein release, an increased 
understanding of the regulatory processes governing pro- 
teolysis will facilitate our understanding of the role of 
spontaneous shedding. 
Antibody-induced shedding 
Treatment of cells with antibodies to specific cell-surface 
molecules promotes receptor shedding in some cases. For 
example, antibodies to the lipopolysaccharide receptor 
CD14 [34], the sialomucin CD43 [8], the hyaluronate 
receptor CD44 [35] and the lymphocyte homing receptor 
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L-selectin (CD6ZL) [36-381 can promote the shedding of 
their respective antigens. The mechanism of antibody- 
induced shedding has been suggested to be dependent on 
the ability of the antibody to cluster its receptor, analo- 
gous to ligand engagement. In such a model, proteolysis 
would be induced by receptor clustering, but antibodies 
can trigger other effects besides simple receptor cluster- 
ing. Consequently, it has been difficult to separate the 
roles of receptor clustering and of \-arious signaling 
processes in antibody-promoted shedding el’ents. 
Several examples in the literature demonstrate that anti- 
bodies to specific receptors can promote the shedding of 
other surface molecules. For instance, treatment of Iym- 
phocytes with antibodies to the signal transduction mole- 
cule Leu-13 [37], the protein tyrosine phosphatase CD45 
[39,40] or the FcyRIII CD16 [41] promotes cleavage of 
I,-selectin. hlonoclonal antibodies that bind to CD95 
(APO-l/Fas, a member of the tumor necrosis receptor 
family) promote the shedding of L-selectin, the 
hyaluronate receptor CD44 [42,43] and several other pro- 
teins. Similarly, anti-CD20 antibodies induce cleavage of 
the IgE receptor CD23 [44]. These data emphasize that 
antibodies function as more than simple cross-linking 
agents; they can activate additional processes, such as 
signal transduction pathway, that result in the shedding 
of other receptors. Antibody-mediated release of some 
proteins is inhibited by protein tyrosine kinase inhibitors, 
but many of these shedding events resemble those pro- 
moted by cellular activation. Given the possibilities, it can 
be difficult to definitively interpret the mechanism(s) of 
antibody-promoted receptor shedding. 
Ligand-induced proteolysis 
There have been several reports describing the proteolytic 
cleavage of proteins in response to ligand engagement. 
Proteins susceptible to this type of proteolysis belong to a 
wide variety of unrelated receptor families, including G-  
protein-coupled receptors, cytokine and growth factor 
receptors and cell-adhesion molecules. Because hgand 
binding can cause signal transduction, the molecular 
events involved in some ligand-induced proteolytic 
processes may overlap with those that are caused by cellu- 
lar stimulants. Alternatively, hgand binding could cause 
changes in protein multimerization or conformation, 
increasing the susceptibility of a receptor to proteolysis. 
Consequently, l igand-promoted proteolysis ma): be a 
general regulatory mechanism (Figure 4) that links protein 
cleavage to protein function. Several proteins that appear 
to be proteolytically cleaved in response to ligand binding 
are discussed in more detail below. 
G-protein-coupled receptors 
Some G-protein-coup1e.d receptors, termed protease- 
activated receptors (PARS) can be stimulated by proteo- 
lytic cleavage (Figure 4a). G-protein-coupled receptors, 
characterized by their seven helical trdnsmembrane do- 
mains, generally transmit information by undergoing a con- 
formational change induced by ligdnd binding. The 
conformational change in PARS is triggered by the binding 
of hgand proteases, such as thrombin (PAR-l, PAR-3) or 
trypsin (PAR-Z). The protease initiates signaling b>- binding 
to its target receptor. and cleaving the receptor near the 
amino terminus, causing a conformation change that creates 
a next site for intramolecular interaction. In\,estigations of 
PARS have revealed an elegant mode by \vhich regulated 
proteolysis can control signal transduction (Figure la) [l]. 
It could be imagined that a similar covalent-bond change 
induced by a hgand could also be used for deactivation of 
a receptor. One feature of the G-protein-coupled signal 
transduction system is that cells tend to become desensi- 
tized after prolonged exposure to ligand. Receptor inter- 
nalization is one consequence of ligand engagement but 
receptor shedding could also play a role in desensitization. 
Circumstantial evidence indicates that se\,eral G-protein- 
coupled receptors are subject to limited proteolysis, 
including the P1-adrenergic receptor [4.5], the endothelin 
ET, receptor [46,47], the \Z \-asopressin receptor [48] and 
the thyrotropin receptor (TSHR) [49,50]. Two examples 
from this receptor class in which l igand-induced shedding 
has been proposed to play an important role are the Yz 
vasopressin receptor and the thyrotropin receptor. 
Kojro d cc/. [-Ml used receptor-containing bovine kidney 
membranes to demonstrate that the Lrr vasopressin recep- 
tor, which mediates the antidiuretic action of the hormone 
vasopressin, is cleaved upon exposure to a vasopressin 
agonist. They proposed that ligdnd engagement exposes 
the cleavage site, allowing cleavage between the second 
transmembrane domain and the first extracellular loop, 
which contains the ligand-binding site. The enzyme, an 
unidentified metalloproteinase. leaves a truncated. mem- 
brane-bound receptor that is no longer able to bind ligand. 
The authors propose that l igand-induced proteolysis can 
attenuate signal transmission between vasopressin and the 
vasopressin receptor (Figure 4b). 
The thyrotropin receptor (TSHR), involved in regulation 
of thyroid cell growth and function and implicated in 
certain autoimmune diseases, also seems to be regulated 
by l igand-induced shedding [WI. TSHR is shed sponta- 
neously from human thyroid cells and transfected cell 
lines. and the shedding is increased upon exposure to the 
ligand, thyrotropin (TSH), as well as PhIA or calcium 
ionophores such as A23187 or ionomycin. TSHR is 
unique in that it is expressed as a heterodimer at the cell 
surface u-here the extracellular CI subunit and the trans- 
membrane spanning p subunit are held together through 
disulfide bonds. It was discovered recently that the 
proteolytic release of the a subunit is dependent on met- 
alloprotease-mediated cleavage followed by a subsequent 
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Figure 4 
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Several receptors appear to be proteolytically released from the cell in response to ligand binding. (a) Thrombin receptor. (b) Vasopressin 
receptor. (c) TrkA receptor. (d) mlL-3 receptor. 
disulfide bond reduction [49]. Release of the cx subunit 
may prevent signal transmission through the TSHR, 
whereas the soluble a subunit may inhibit binding of 
TSH to intact receptors on the cell surface. Although the 
relative importance of ligand-induced proteolysis of 
TSHR and ligand-induced receptor downregulation has 
not been determined, the proteolytic shedding may mod- 
ulate receptor-ligand interactions in this system. 
Cytokine and growth factor receptors 
Several cytokine and growth factor receptors, including the 
tumor necrosis factor receptors (TNFRs), the TrkA neu- 
rotrophin receptor and the murine IL-3 receptor (mIL-3R), 
are proteolytically released from the cell surface upon 
exposure to either their cognate ligands or agonists 
(Table 1). The mechanisms of ligand-induced shedding of 
these receptors are not well understood; conformational 
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change, receptor dimerization or receptor clustering upon 
ligand binding may contribute to the signal for proteolytic 
cleavage. There is also evidence that phosphorylation is 
involved in the ligand-induced shedding of some of these 
receptors, either as a signal for cleavage, as in the mIL-3R, 
or as a consequence of cleavage, as in the TrkA receptor. 
Soluble forms of TNF-a and its two receptors (~5.5 TNFR 
and ~75 TNFR) can be generated by proteolytic cleavage 
[Sl-541. High levels of soluble TNFR can be found in 
patients who have elevated TNF levels, suggesting a link 
between the formation of soluble TNFR and TNF 
[.55,56]. Although the majority of studies on the shedding 
of the ~55 TNFR and ~75 TNFR have investigated the 
cleavage induced by phorbol ester stimulants [S7-601, 
several reports suggest that TNF-cx promotes the shedding 
of its receptors. Although some have suggested only the 
~75 TNFR is susceptible to ligand-promoted shedding 
[61,62], others indicate that TNF-cx can stimulate the 
release of both ~55 and ~75 TNFRs [.58,63,64]. Analysis of 
the complex of the related ligand TNF-fi and ~55 TNFR 
revealed that the trimeric ligand was bound to three copies 
of the receptor [65]. Thus, it appears that the trimeric 
TNF ligands induce a change in receptor organization. 
Whether this altered conformation is recognized by a pro- 
tease or whether the signals transduced by the receptor 
lead to protease activation is not known. 
The observations that the shedding of TNF-cx and TNFR 
appear to be connected and the uncharacterized enzyme 
that proteolytically releases TNFR is similar to that 
responsible for TNF-a shedding have important thera- 
peutic ramifications. Protease inhibitors that block pro- 
duction of TNF-cx may simultaneously inhibit TNFR 
shedding, increasing the cellular response to low levels of 
TNF-a. Manipulation of the inflammatory response 
through these receptor-ligand pairs requires selectivity, 
provided by, for example, agents that inhibit the release of 
TNF-a but do not prevent the release of its receptors. 
Alternatively, the discovery of molecules that promote the 
cleavage of the TNFRs without affecting TNF-ol could 
be useful modulators of the inflammatory response, but, to 
date, no such molecules have been described. 
The receptor tyrosine kinase TrkA, which is involved in 
the development and survival of neural cells, appears to 
undergo ligand-promoted shedding (Figure 4~). A TrkA 
ligand, nerve growth factor (NGF), was found to promote 
ectodomain proteolysis of the TrkA receptor, which 
results in the production of a fragment composed of a 
transmembrane region and an intracellular kinase domain 
[66]. The remaining membrane-bound fragment had a 
greater phosphotyrosine content than its intact counter- 
part, and the increase was attributed to autophosphoryla- 
tion. Interestingly, the augmented level of kinase activity 
was probably a consequence of the cleavage, not the cause 
of it, as TrkA isozymes with defective kinase domains 
were also shed. Like the growth factor ErbB-4 discussed 
previously, the kinase domain of the cleavage product is 
active but no longer subject to regulation. In various 
tumor cell lines, constitutively active mutants of receptor 
tyrosine kinases are often truncated cell-associated recep- 
tors that lack their extracellular domains. Thus, the 
release of the extracellular domain, and therefore the 
signal triggered by the kinase-active fragment must be 
regulated to prevent unwanted signaling events. As with 
many other shed proteins, the soluble fragment generated 
upon release could modulate the effects of the ligand. 
Although some receptor tyrosine kinases, such as the 
TrkA receptor, are activated upon release of their extra- 
cellular domain, receptor cleavage may also be induced by 
phosphorylation. The murine IL-3 receptor (IL-3R) is 
phosphorylated and then shed upon binding of IL-3 
(Figure 4d) [67]. Mui et a/ found that receptor phosphory- 
lation accompanied proteolytic release of the p subunit, 
but that unmodified IL-3R is not a substrate for cleavage. 
The authors propose that ligand binding to the IL-3R 
results in phosphorylation of its intracellular domain, 
which triggers its cleavage. In analogy to the proposed sit- 
uation for TNF binding by TNF-R, the extracellular 
domain could be downregulated on the cell surface, and 
the soluble form of the receptor could regulate IL-3- 
mediated signal transduction. 
Cell-adhesion molecules 
Soluble forms of several cell-adhesion molecules are 
detected in circulation (Table 1). Many are shed constitu- 
tively or upon cell activation, but there is increasing evi- 
dence that ligand binding may promote the shedding of at 
least some of these proteins. In addition to the notion that 
antibody-induced shedding of CD43 [8], CD44 [35] and 
L-selectin (CD62L) [36-381 is analogous to ligand- 
induced shedding, some reports imply that shedding may 
be associated with cell adhesion [68] or migration [69]. 
Ligand-dependent shedding of cell-adhesion molecules 
may function in part to promote the de-adhesion process, 
a necessary component of cell-cell interactions. 
L-Selectin is a cell-adhesion molecule involved in the 
inflammatory response, and the shedding of L-selectin is 
unusual because it can occur by at least two apparently 
independent pathways: by induction with cellular stimu- 
lants and with multivalent L-selectin ligands (Figure 5). 
L-Selectin mediates an early step in leukocyte recruit- 
ment to the endothelium - the rolling of leukocytes 
along the endothelial cell wall. L-Selectin is shed rapidly 
from neutrophils and lymphocytes upon treatment with 
phorbol esters, an event that can be blocked using zinc 
metalloproteinase inhibitors (hydroxamic acid deriva- 
tives). The activation-induced shedding of L-selectin 
coincides with the appearance of increased levels of the 
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Figure 5 
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The proteolytic release of L-selectin can be 
induced with cellular stimulants or multivalent 
L-selectin ligands. These processes are 
distinct: cellular stimulants cause upregulation 
of the PP-integrin Mac-l, but synthetic ligands 
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PZ-integrin hlac-1 in neutrophils. P2-integrins also func- 
tion in the leukocyte recruitment process, mediating the 
firm leukocyte-endothelium adhesion that follows rolling. 
The concomitant stimulant-promoted downregulation of 
L-selectin and upregulation of the PZ-integrins suggests 
that the coupling of events is not merely circumstantial. 
Anti-L-selectin antibodies can also promote L-selectin 
shedding [36-381, a result that suggests ligand binding and 
or receptor clustering might regulate the display of 
L-selectin on the cell surface. Because antibody engage- 
ment of other cell-surface molecules like CD45 also trig- 
gers L-selectin release [39,40], the antibody-promoted 
shedding experiments are difficult to interpret. 
To gain insights into the relationship between L-selectin 
binding, clustering, and proteolytic release, Gordon et nl. 
[70] directly investigated the effects of L-selectin ligands 
on the cell-surface presentation of the protein. The 
known physiological L-selectin ligands, GlpCAll-1 [71], 
CD34 [72], and PSGL-1 [73], are mucin-like glycopro- 
teins that display multiple copies of an L-selectin binding 
epitope (derivatives of the tetrasaccharide sialyl Lewis X) 
[74,75] on their surface. The development of methods to 
synthesize monovalent and multivalent derivatives pro- 
vided the means to investigate whether L-selectin ligands 
could promote shedding and, if so, to ascertain which 
structural features are required. hlonovalent derivatives of 
the trisaccharide Lewis X, which are L-selectin inhibitors 
(IC,,, values of 1-3 mhl) [76]. did not cause L-selectin 
shedding. In contrast, the synthetic multivalent ligands 
(termed neoglycopolymers) induced L-selectin shedding 
from human leukocytes in a dose-dependent manner 
(Figure 6). 
Intriguingly, the proteolytic cleavage of I,-selectin in- 
duced by the neoglycopolymers \vas quite distinct from 
that observed with other agents. One important differ- 
ence is that the polymer-promoted cleavage appears to 
selectively initiate I,-selectin shedding (E.J.G. and P.A. 
hlowery, unpublished observations), whereas the activa- 
tion-promoted process results in the cleavage of a number 
of surface molecules. In addition, the neoglycopolymer- 
treated leukocytes showed no signs of activation, as deter- 
mined by the lack of increase in the surface concentration 
of the PZ-integrin hlac-1 (Figure 5). Thus, integrin upreg- 
ulation and L-selectin downregulation are not necessaril! 
coupled events, which is important as it may be therapeu- 
tically useful to minimize cell-surface lel-els of L-selcctin 
without simultaneously initiating other signaling path- 
ways. The polymer-induced shedding was not inhibited 
by the PKC inhibitor staurosporine, which blocked the 
PhlA-stimulated cleavage. Surprisingly, a hydroxamic- 
acid based metalloproteinase inhibitor, which diminishes 
activation-induced shedding, also had no effect on activity 
of the neoglycopolymer [70]. These results demonstrate 
the multivalent, but not monovalent, synthetic ligands 
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Figure 6 
Synthetic models designed to mimic 
physiological L-selectin ligands. Only the 
multivalent molecule, 3’,6-disulfo LeX 
neoglycopolymer (right) induces the cleavage 
of L-selectin from the surface of leukocytes. 
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can initiate L-selectin shedding, and they suggest that the 
ligand-induced shedding process has unique features that 
can be exploited. 
To date, ligand-induced shedding of cell-adhesion mole- 
cules other than L-selectin has not been explored widely. 
Nevertheless, there is some evidence that suggests that the 
hyaluronic acid receptor, CD44, may also be proteolyzed 
upon ligand binding. CD44 is implicated in various cellular 
processes, including lymphocyte binding to HE\:, T cell 
activation, monocyte stimulation to IL-1 production and 
lymphopoiesis [77]. It is interesting to note that, like L- 
selection, CD44 can mediate lymphocyte rolling, and 
therefore it may have a similar biological role [78]; CD44, 
again like L-selectin, binds a saccharide derivative-- 
hyaluronic acid, a linear, anionic polysaccharide that could 
engage CD44 in multivalent binding. This process could 
cause receptor clustering, which might trigger the prote- 
olytic release of soluble CD44. In a recent report by Fried1 
et al. [69] the migration of highly aggressive hIV3 mela- 
noma cells was shown to be accompanied by shedding of 
CD44. Loss of CD44 from the surface of the cells subse- 
quent to ligand engagement could serve to assist the migra- 
tion of cells by promoting their detachment, suggesting 
that the shedding of CD44, induced by adhesion, may not 
only assist in normal cell migration, but may also contribute 
to the metastasis of cancer cells. 
The mechanism of receptor shedding 
Given the number of proteins that can be shed, elucidat- 
ing the mechanisms that control protein shedding is an 
important goal. The widespread shedding induced by 
phorbol esters is intriguing as it suggests there may be a 
general control mechanism to render a cell resistant to a 
multitude of extracellular signals. Alternatively, the ligand- 
induced processes may represent specific cases in which 
selected receptors are released preferentially in response 
to particular activation pathways. Ligand-induced shed- 
ding could result in a conformational change, dimerization 
or clustering of the receptor, thereby generating a recogni- 
tion site for a protease. In this case, the protease itself is 
constitutively active, and is only dependent on the genera- 
tion of a recognition site for shedding to occur. This would 
explain how some receptors are shed constitutively at low 
levels, whereas the shedding can be upregulated after 
exposure to ligand. Interestingly, some of the metallopro- 
teinases are thought to act in multimeric form [ZO]. 
To focus on various events that lead to protein ecto- 
domain release, we have divided different shedding 
processes into categories. These divisions provide a 
context in which to introduce specific examples, but little 
is known about the regulatory mechanisms governing the 
proteolytic release of ectodomains. hloreover, it often is 
difficult to distinguish among activation-, antibody- or 
ligand-induced shedding for a given set of experimental 
conditions. For example, ligands binding to receptor tyro- 
sine kinase proteins will activate specific signaling path- 
ways. Thus, shedding could be brought about by a 
change in the state of the receptor, such as oligomeriza- 
tion and/or phosphorylation, or an alteration of the pro- 
tease, such as activation by a signal transduction cascade 
or a change in localization. The cell type, culture condi- 
tions, isolation/purification procedures, and shedding 
agents used, as well as the signal transduction pathways 
initiated can all dramatically affect cell behavior so com- 
paring and analyzing results from different experiments is 
extremely complex and it is difficult to draw conclusions. 
Future directions 
The proteolytic release of a protein ectodomain can have 
several consequences. The cell-surface concentration of 
the protein decreases, and, if the protein is a receptor, 
ligand binding at the cell surface will also decrease, desen- 
sitizing the cell to the effects of the ligand. Simultane- 
ously, the concentration of the soluble and potentially 
biologically active form of the receptor in circulation will 
be increased. Thus, the soluble form of the receptor can 
function as an inhibitor of receptor-l&and interactions or 
as a transporter of the ligand, removing the ligand from 
the cell surface and enhancing its stability in circulation. 
For proteins that have intracellular phosphorylation sites 
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or intrinsic kinase activity, receptor shedding may result in 
activation or deactivation of a signaling pathway. Alterna- 
tively, the shed molecules themselves can activate signal- 
ing pathways in other cells, as is observed with cytokines. 
Collectively, these events have the potential to dramati- 
cally alter the extracellular environment and affect cell 
behavior at adjacent and distant sites. Despite the wide- 
spread occurrence of protein shedding, however, little is 
known about the molecular events that regulate the 
process. The development of molecules that can either 
inhibit or promote the release of cell-surface proteins pro- 
vides new opportunities for initiating or preventing spe- 
cific extracellular recognition and signaling events. Such 
agents can be used to illuminate the events leading to 
shedding in addition to serving as new therapeutic leads. 
Soluble forms of many receptor proteins are present in cir- 
culation in normal, healthy individuals but, in many dis- 
eases, concentrations of these receptors are altered, 
indicating that the ability to manipulate receptor shedding 
may have significant therapeutic potential [56,79]. For 
example, increased concentrations of TNF-a may con- 
tribute to the pathogenesis of several diseases, such as 
rheumatoid arthritis, insulin-dependent diabetes mellitus, 
HIV and sepsis. Strategies to prevent the cell surface 
release of TNF-a, including the use of several metallopro- 
teinase inhibitors, are under development [80]. As many of 
the agents that block the activation-induced release of 
TNF-a also inhibit the shedding of other proteins, in addi- 
tion to leading to new anti-inflammatory treatments, these 
studies will give an insight into the physiological roles of 
shedding and its importance. Blocking the release of other 
proteins may uncover additional therapeutic applications. 
Protein activity can potentially be controlled by initiating 
the shedding of particular proteins but this method is 
largely unexplored. Selective agents that induce the prote- 
olytic release of a specific receptor can protect cells from 
the actions of a deleterious ligand. In addition, the soluble 
form of the receptor may act to sequester the damaging 
ligand. Moreover, selective activation of a protease could 
have significant therapeutic advantages. For example, the 
p amyloid (AP) peptide (the major protein component of 
the amyloid plaques found in Alzheimer’s patients) is gen- 
erated by proteolytic processing of the P-amyloid precur- 
sor protein (BAPP). Interestingly, a protease, known as 
a-secretase, cleaves the pAPP within the AD sequence, 
precluding the formation of AD and its subsequent aggre- 
gation that can lead to plaque formation [81,82]. Increased 
a-secretase cleavage could prevent the accumulation of 
AD, which may be beneficial in Alzheimer’s disease. 
An important factor in designing molecules that pro- 
mote shedding is that, because an endogenous enzyme 
promotes the cleavage, substoichiometric amounts of 
the shedding agent could be used. Not only does the 
proteolytic shedding of proteins therefore have the 
potential to occur catalytically, but, unlike noncovalent 
binding, it is also irreversible. These are inherent advan- 
tages that are absent from other strategies. The discovery 
that compounds based on glycoproteins selectively 
promote the shedding of L-selectin demonstrates that 
synthetic ligands can be used to modulate cell-surface 
display through proteolytic release. This result suggests 
new directions for controlling both the display of cell- 
surface proteins and the concentration of soluble proteins 
in circulation. 
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